Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Article - 30/08/2010 12218_de.jpg

    Bodensee Brustzentrum offers effective breast cancer prevention services

    The two Brustzentrum Bodensee (Lake Constance Breast Centre) sites at the Hospital in Constance and the Women’s Hospital in Friedrichshafen have a principal goal: to enable the best possible early detection of all types of breast cancer, to reduce the morbidity and mortality of breast cancer patients and to increase survival rates by offering ultra-modern breast cancer prevention measures.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/bodensee-brustzentrum-offers-effective-breast-cancer-prevention-services
  • Article - 24/07/2017 The figure shows a model of the IDH1 complex. Two polypeptide chains (brown and light blue) form a dimer between which the substance BAY 1436032 (yellow) binds.

    Cancer medicine development as a science and industry partnership

    The German Cancer Research Center (DKFZ) and Bayer AG are collaborating on a strategic partnership focusing on the development of innovative cancer therapies. The two partners have developed an active substance which selectively blocks a mutation of a metabolic enzyme that occurs in certain types of cancer. The substance has been successfully tested in preclinical studies and is now also being tested in a clinical trial on patients with brain…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/cancer-medicine-development-as-a-science-and-industry-partnership
  • Press release - 03/12/2018

    SpinDiag closes second financing round of EUR 3.0 million (USD 3.4 million) to complete product development of its point-of-care screening system for antibiotic-resistant bacteria

    One year after its seed financing, SpinDiag GmbH closes a second financing round of EUR 3 million (USD 3.4 million) as planned. The financing will enable SpinDiag to complete the product development of its first product for screening for antibiotic-resistant bacteria and to start clinical trials. This will pave the way for regulatory approval in the EU.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/spindiag-closes-second-financing-round-of-eur-30-million-usd-34-million-to-complete-product-development-of-its-point-of-care-scr
  • Press release - 30/07/2009

    Boehringer Ingelheim set to outpace the market again

    After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
  • Article - 07/03/2017 Seven people holding a check indicating the donated sum of 20.000.000 euros.

    KiTZ: Hopp Children’s Tumour Center at NCT Heidelberg

    The Heidelberg University Hospital and the DKFZ have established the "Hopp Children's Tumor Center at NCT Heidelberg" (KiTZ) where doctors, scientists, nursing staff and other specialists work side by side on new diagnostic and therapeutic options to help children with cancer.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/kitz-hopp-childrens-tumour-center-at-nct-heidelberg
  • Press release - 09/01/2012 Logo apogenix

    Apogenix Raises 7.5 Million Euros to Further Advance APG101 to Treat Glioblastoma and other Tumors

    The biopharmaceutical company Apogenix GmbH today announced the successful completion of a € 7.5 million financing round led by dievini Hopp BioTech holding GmbH & Co. KG (dievini). Other investors include the German Cancer Research Center (DKFZ), the founders and the executive management team of Apogenix. These funds will enable Apogenix to further advance the phase II clinical trial of APG101 to treat Glioblastoma Multiforme (GBM) and other…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-raises-7-5-million-euros-to-further-advance-apg101-to-treat-glioblastoma-and-other-tumors
  • Press release - 02/02/2012 Immatics Logo

    Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive
  • Article - 24/05/2017 A small moss plant on a finger.

    Ralf Reski: from moss to humans

    Prof. Dr. Ralf Reski conducts basic research at the University of Freiburg. But this is not all the well-known plant biotechnologist does. He also wants his ideas to become concrete products. This is why he established Greenovation Biotech GmbH, a company which produces novel drugs in mosses. The company’s first moss-produced drug candidate – Moss-aGal – a recombinant form of human α-galactosidase, is now being tested in a phase I clinical trial.…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ralf-reski-from-moss-to-humans
  • Article - 18/01/2018 Teaser-Mutationen-Primartumor.png

    Medications that target metastasing tumours

    Tumour metastases are often resistant to the drug that is used to eliminate the primary tumour. Genome-wide analyses of mutation patterns in the primary tumour and its metastases provide information on the aggressiveness of cancer and may help to find the best available means of further treatment. This has been demonstrated by scientists from Heidelberg in a clinical trial on the molecular evolution of renal cancer.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/medications-that-target-metastasing-tumours
  • Article - 18/01/2016 The photo shows two blister packs with tablets.

    New approaches in the life sciences industry: innovative strategies for courageous companies

    For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
  • Press release - 02/11/2011 15730_de.jpg

    Using Viruses to Fight Brain Tumors

    Parvoviruses can enter and kill cancer cells, but they do not cause disease in humans. Since 1992, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have been studying these viruses with the aim of developing a viral therapy against dangerous brain tumors that are almost impossible to treat.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/using-viruses-to-fight-brain-tumors
  • Company profile - 04/09/2017 Colour photo of Prof. Dr. François Paquet-Durand (left) and Barbara Brunnhuber (right).

    Mireca: a new drug for stopping the progression of eye diseases

    A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/mireca-a-new-drug-for-stopping-the-progression-of-eye-diseases
  • Expert interview - 14/11/2016 The photo shows a green plant.

    The great untapped potential of herbal medicines

    Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-great-untapped-potential-of-herbal-medicines
  • Article - 11/12/2008

    New drug that targets metastasing breast cancer in clinical phase III trial

    Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-drug-that-targets-metastasing-breast-cancer-in-clinical-phase-iii-trial
  • Dossier - 10/11/2014 22065_de.jpg

    Cell and gene therapies: from bench to bedside

    While cell therapy has become standard treatment for a number of blood cancers, most cell and gene therapy approaches for the treatment of hereditary and metabolic diseases, neurodegenerative disorders and cancer are still in the experimental phases or early clinical trials. However, recent successes give rise to the hope that cell and gene therapies will in future make important contributions to previously incurable diseases.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/cell-and-gene-therapies-from-bench-to-bedside
  • Article - 09/01/2012 16152_de.jpg

    Biomarkers to combat lung cancer

    A biomarker-driven personalised therapeutic approach to lung cancer is possible – this is the conclusion reached by the BATTLE trial. The preliminary results of the trial were summarised by scientists from the Thoraxklinik at Heidelberg University Hospital in the May 2011 issue of “Clinical Investigation”.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/biomarkers-to-combat-lung-cancer
  • Press release - 07/08/2012 Immatics Logo

    immatics announces publication of IMA901 cancer vaccine data in Nature Medicine

    immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine. The paper highlights that renal cell carcinoma patients experience longer survival times when their immune system produces an immune response to…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-publication-of-ima901-cancer-vaccine-data-in-nature-medicine
  • Affimed GmbH - 01/07/2020 Schematische Darstellung der Kommunikation zwischen den Zellen der angeborenen und erworbenen Immunität. „innate cell engager“ aktivieren NK-Zellen und Makrophagen, die wiederum tumorspezifische T-Zellen stimulieren.

    "Innate cell engagers" to fight cancer

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/innate-cell-engager-fighting-against-cancer
  • Article - 01/08/2008

    Nycomed - collaboration with Immunomedics

    Under the agreement Nycomed will receive the exclusive worldwide rights to develop manufacture and commercialise the subcutaneous formulation of veltuzumab for the treatment of all non-cancer indications.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-collaboration-with-immunomedics
  • Press release - 21/10/2009 09805_de.jpg

    Meyenburg Award 2009 for the First Targeted Anti-Cancer Drug

    The 2009 Meyenburg Award for Cancer Research with an award sum of 50,000 euros goes to American blood cancer expert, Brian Druker. The Meyenburg Foundation honors Druker as a pioneer of molecularly targeted cancer therapies for developing the leukemia drug Imatinib (Gleevec). Druker’s work has turned chronic myeloid leukemia from a deathly threat into a treatable disease for many patients today. The Meyenburg-Award has been presented on…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/meyenburg-award-2009-for-the-first-targeted-anti-cancer-drug
  • Press release - 17/06/2020

    CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
  • Article - 16/01/2012 The photo shows fifteen people standing in front of a building.

    Manfred Jung: drug discovery and the epigenetic code

    Prof. Dr. Manfred Jungs team at the University of Freiburg are chemical epigeneticists whose research involves the development of methods that enable them to identify and optimise new therapeutic drugs which are able to alter the epigenetic code of cancer and other cell types. The team use a perfidious worm for their research.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/manfred-jung-drug-discovery-and-the-epigenetic-code
  • Article - 05/04/2018 Translational cancer research is able to bridge the valley of death. The drawing shows a bridge spanning the two valleys of death in medical research - one between preclinical and clinical research and another between the clinical efficacy of drugs as demonstrated by clinical trials and the evidence of real benefits for patients and society.

    Crossing the valley of death with translational cancer research

    It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/crossing-the-valley-of-death-with-translational-cancer-research
  • Press release - 18/09/2009

    Affimed Therapeutics AG receives FDA Orphan Drug Designation for AFM13 against Hodgkin Lymphoma

    Affimed Therapeutics AG announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to the human recombinant antibody AFM13 for the treatment of Hodgkin lymphoma. The designation entitles Affimed to seven-year market exclusivity in the US upon approval of this drug candidate. AFM13 is a novel, bispecific antibody based on Affimed's proprietary TandAb technology.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-therapeutics-ag-receives-fda-orphan-drug-designation-for-afm13-against-hodgkin-lymphoma
  • Press release - 24/01/2011 13484_de.jpg

    Synimmune - Close cooperation cuts new cancer drug development time

    A development project from Synimmune GmbH, founded in July 2010, made a big impression on the panel of assessors at the German Federal Ministry of Education and Research (BMBF). So much so, that the company was awarded EUR 2.5 million as part of the GO-Bio biotechnology start-up scheme.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/synimmune-close-cooperation-cuts-new-cancer-drug-development-time

Page 3 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search